HIV DNA vaccine - FIT Biotech/IAVI

Drug Profile

HIV DNA vaccine - FIT Biotech/IAVI

Alternative Names: DNA-GTU vaccine; FIT-06; GTU MultiHIV; GTU-multi-HIV B clade DNA vaccine; GTU®-multiHIV B Clade Vaccine

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator FIT Biotech
  • Developer FIT Biotech; Imperial College of Science, Technology and Medicine
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-infections(New delivery system) in Finland (Parenteral, Liposomal)
  • 01 Nov 2016 FIT Biotech plans a phase IIb trial for HIV infections (Prevention) in United Kingdom and France (NCT02972450)
  • 24 Jul 2015 HIV DNA vaccine is still in active development in Finland and South Africa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top